AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05221645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
Study NCT06119854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attitudinal inoculation
Description: A brief video focused on bolstering resistance to mis/disinformation about the COVID vaccine. Participants will receive two messages via text or email (1 and 3 days after the inoculation intervention). These messages will include reminders to get vaccinated.
Study NCT06119854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy-informed intervention
Description: A brief video using a CBT-informed approach and focused on addressing barriers to COVID-19 vaccination. Participants will receive two messages via text or email (1 and 3 days after the inoculation intervention). These messages will include reminders to get vaccinated.
Study NCT06119854 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional public health messaging
Description: A brief video conveying conventional public health messaging adapted from a review of public health public service announcements with no inoculation messaging. Participants will receive two messages via text or email (1 and 3 days after the inoculation intervention). These messages will include reminders to get vaccinated.
Study NCT04734860 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-AMG
Description: COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
Study NCT04734860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent solution
Study NCT04840017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation exercise
Description: Rehabilitation exercise of intrinsic foot muscles
Study NCT06101082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous infusion anti-HER2-CAR-T cell
Description: Anti-HER2-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 1×10\^6 CAR-T cells/kg, 3×10\^6 CAR-T cells/kg, and 1×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
Study NCT06356948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: Study drug administration
Study NCT05530343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Seattle protocol
Description: Participants undergo 4-quadrant biopsies with standard biopsy forceps taken at 2 cm intervals. For participants undergoing a confirmatory endoscopy for cases in which discordant results are noted (WATS3D positive for dysplasia/cancer and Seattle biopsy negative for dysplasia/cancer), repeat biopsies will be taken at 1 cm intervals along with target biopsies from any visible lesions.
Study NCT05530343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: WATS3D brushings
Description: Participants undergo 2 WATS3D biopsies of every 5 cm segment of Barrett's esophagus, starting from the gastroesophageal junction and moving proximally through the entire segment of Barrett's.
Study NCT05483803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adhera® Caring digital intervention for Type 1 Diabetes
Description: The Adhera® Caring is a mobile based personalized digital intervention for caregivers, lasting for 1 or 3 months (depending on the sub-study).
Study NCT04835649 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Both groups will receive exercise-based training
Study NCT04835649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups will receive exercise-based training
Study NCT06219993 — intervention group
Intervention type: PROCEDURE
Intervention: robot-assisted modified Kasai portoenterostomy
Description: 1. A 1.0 cm incision was made around the umblilicus for the camera port. 1.Firstly, the Exploring hepatic subcapsular spider-like telangiectasis (HSST) sign at the surface of the liver, and indocyanine green (ICG) cholangiography were observed to confirm the BA diagnosis.~2. dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With electric scissors help, the fibrous plate was horizontally cut from the middle of the portal plate and transected from to the left and to the right sides which was the Glissonian systems enter the liver parenchyma until see the bile outflow by verified by ICG. The opening of microbile ducts and abundant bile outflow were clearly visible under 10× camera of Da Vinci robot.
Study NCT06219993 — intervention group
Intervention type: PROCEDURE
Intervention: traditional open Kasai portoenterostomy
Description: Dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With scissors help, the fibrous cone of the hilar region was transected from left to right (the level of transection depends on adequate bile outflow).
Study NCT05732974 — intervention group
Intervention type: OTHER
Intervention: Resected non small cell lung cancer
Description: plasma sample, tissue sample and computed tomography scan images
Study NCT04591041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HoloSIM Software via Hololens 2
Description: Medical students will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
Study NCT04475991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Currently used therapy
Description: Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)
Study NCT04591041 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training by Mannequin Based Simulation
Description: Medical students will train a via traditional mannequin based medical crisis scenario
Study NCT04475991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curently used therapy for COVID-19 non-critical patients
Description: Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga
Study NCT05370755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-189
Description: Administered orally
Study NCT04475991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir + Currently used therapy
Description: Favipiravir tablets 200 mg. given orally for a 7 day period. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga).
Study NCT05614557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratacel
Description: Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
Study NCT05614557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratamed
Description: Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
Study NCT04693689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RNA vaccine
Description: We elicit subjects' willingness to receive RNA COVID-19 vaccine
Study NCT04103476 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
Description: Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
Study NCT04103476 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05918978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Description: Participants will receive efgartigimod IV 10 mg/kg open label, respectively.
Study NCT04693689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% adoption rate
Description: We elicit subjects' willingness to receive the new vaccine if 20% of the country's population has received it
Study NCT04693689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40% adoption rate
Description: We elicit subjects' willingness to receive the new vaccine if 40% of the country's population has received it
Study NCT04693689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60% adoption rate
Description: We elicit subjects' willingness to receive the new vaccine if 60% of the country's population has received it
Study NCT04693689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 80% adoption rate
Description: We elicit subjects' willingness to receive the new vaccine if 80% of the country's population has received it
Study NCT04693689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional vaccine
Description: We elicit subjects' willingness to receive conventional COVID-19 vaccine
Study NCT04693689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0% adoption rate
Description: We elicit subjects' willingness to receive the new vaccine if 0% of the country's population has received it
Study NCT06027073 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: omalizumab
Description: adding omalizumab to anti asthmatic therapy
Study NCT04619004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab Deruxtecan (Fixed dose)
Description: Patritumab deruxtecan will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
Study NCT04619004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab Deruxtecan (Up-Titration)
Description: Patritumab deruxtecan will be dosed as an intravenous (IV) infusion administered at Cycle 1, 3.2 mg/kg; Cycle 2, 4.8 mg/kg; Cycle 3 and subsequent cycles, 6.4 mg/kg administered on Day 1 of each 21-day cycle.
Study NCT06483854 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV counseling and testing from a traditional health practitioner
Description: Healer provided HIV counseling and testing services offered to clients
Study NCT06340230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 Injection + Adebrelimab Injection
Description: Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
Study NCT06340230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 Injection
Description: Drug: SHR-A1811 Injection
Study NCT06226051 — intervention group
Intervention type: DEVICE
Intervention: PEAPOD Infant Body Composition measuring device
Description: PEAPOD is a device to that collects body composition measurements.
Study NCT05776524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m2 weekly, on days 1,8, and 15 or on days 1 and 15 as a 30-40 minute infusion administered first
Study NCT05776524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 weekly, on day 1,8 and 15 or 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab- paclitaxel infusion
Study NCT05776524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraBionic
Description: This treatment consists of delivering low levels of radio waves into the body with a spoon-shaped antenna placed in the mouth, three times a day, for an hour each time.
Study NCT05791864 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-381
Description: One time subretinal dose in study eye
Study NCT04718909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib + sintilimab
Description: Regorafenib: 160 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).~Sintilimab: 200mg i.v. q3w.
Study NCT04718909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: 160 mg p.o. qd for 3 weeks of every 4 week cycle.
Study NCT04946487 — intervention group
Intervention type: PROCEDURE
Intervention: total laminectomy
Description: Total laminectomy removes the posterior ligamentous complex (PLC) at the fusion and superior levels.
Study NCT05801367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
Study NCT05801367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allium Sativum Oil
Description: Allium sativum oil will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
Study NCT04761016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The current I-POP health model includes: 1) BSW HWC primary care medical home (for uninsured or Medicare patients), 2)BSW HWC providing diabetes prevention, nutrition education, weight loss, farm stands, physical activity programming (in collaboration with its onsite City of Dallas Park and Recreation Center), 3) BSW HWC programming at community sites in 75210, 4) Referrals to Parkland Hatcher Station clinic that provides health care to Medicaid patients, 5) Referrals between Parkland Hatcher Station and BSW HWC programming, 6) Community improvement in collaboration with Frazier Revitalization Inc. Individuals will have access to resources within our current, ongoing I-POP Health model, but without CHW navigation between BSW HWC and local service providers. Participants will complete follow-up visits for collection of study measures with study personnel at 6- and 10- months. At the end of the 10-month follow-up period, participants receive an assigned CHW and CHW-navigation.
Study NCT04761016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-POP + CHW navigation
Description: Individuals randomized to this condition will be paired with a CHW to assist with navigation of I-POP Health resources at BSW HWC and entities in local zip codes. CHW navigation will occur through monthly one-on-one follow-up visits for a period of 10-months. Participants will complete study visits for collection of data measures at baseline, 6- and 10- month timepoints. Study participation ends with completion of 10-months data measures.
Study NCT06392412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fi-VR Cognitive Training
Description: All participants will 16 sessions over eight weeks, with two sessions per week, each lasting 70 minutes. Participants in the fi-VRCT will use the virtual reality system with head-mounted display and handheld controllers. The fi-VRCT will be administered by an experienced research assistant.
Study NCT06392412 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Cognitive Training
Description: All participants will 16 sessions over eight weeks, with two sessions per week, each lasting 70 minutes. The CT control program will include cognitive board games designed to improve various cognitive capacities. Certified community occupational therapists will lead the CT control group.
Study NCT06573008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 40mg
Description: 2 x 20mg tablets taken orally
Study NCT06573008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GP681 Simulant
Description: Placebo tablets matching GP681 40mg
Study NCT05476653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI procedure
Description: Pulmonary MRI based on a 1.5 T machine (Siemens VIDA) or a 3T machine (Siemens SOLA) without the use of contrast product according to a protocol based on a 3D-UTE sequence acquired in free breathing but with a respiratory synchronization system in association with weightings in T1 and T2.
Study NCT06378437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-001
Description: Administered orally according to the assigned treatment schedule
Study NCT05956587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion
Study NCT05956587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: Administration by intravenous infusion
Study NCT06646952 — intervention group
Intervention type: DRUG
Intervention: 18F-FDG
Description: All study participants will undergo one 18F-FDG PET/ CT scan.
Study NCT04805996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes remission using total diet replacement and eHealth contact with the healthcare provider
Description: Participants will replace usual foods with the commercially available total diet replacement Modifast (Impolin AB), which is delivered to them during the study period without any cost. Participants will be supplied with a scale, a finger-stick blood glucose meter and a blood pressure monitor and will be advised to measure body weight, fasting blood glucose and blood pressure every morning. The results are registered in the mobile phone application Telia Health Monitoring (Telia Sweden AB) and are wirelessly transmitted to the study team.
Study NCT05200559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized monoclonal immunoglobulin (Ig) G4 antibody that inhibits lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response, allowing the immune system to target and destroy cancer cells.
Study NCT05200559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7777
Description: E7777 or denileukin diftitox is a recombinant cytotoxic fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met1-Thr387)-His and for human interleukin-2 (Ala1-Thr133), indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.
Study NCT05887791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate
Description: Single dose
Study NCT05887791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose
Study NCT06237634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: splint and exercise and advices
Description: A hand-wrist support splint and tendon shifting exercises were applied to the upper extremity of the affected side.
Study NCT06237634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: splint and exercise and advices
Description: A hand-wrist support splint and tendon shifting exercises were applied to the upper extremity of the affected side.
Study NCT06237634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Triamsinolon Asetonid ozone
Description: 40 mg (1 ml) of triamcinolone acetonide was injected to the median nerve's around at wrist level under ultrasound guidance.
Study NCT06237634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone
Description: In addition to the treatment and recommendations given to the first group, the affected side was injected with ultrasound-guided 3 cc ozone (O2-O3) into the wrist with a concentration of 10 micrograms/ml.
Study NCT05715060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Median sternotomy closure (sternal closure)
Description: Comparison of Sternal closure after cardiac surgery between conventional way which is by stainless steel wire \& Polydioxanone (PDS)
Study NCT05573139 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of muscle strength by manual dynamometry
Description: The reliability and validation of a new manual dynamometer was verified, compared to one already used, in the muscle groups: knee extensors and flexors; hip extensors, flexors, abductors, adductors, internal and external rotators.
Study NCT05948189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise program
Description: The participants of the intervention group received back health education (Back School) in the classroom. After the education program, they participated in exercise training for six weeks (one day a week).
Study NCT05317598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kindness and honesty psychoeducation based on positive psychotherapy: The Key Model Of Courtesy And Integrity (KMCI)
Description: It is an application that investigates the effect of kindness and honesty psychoeducation based on positive psychotherapy on effective communication skills of nursing students.
Study NCT05548764 — intervention group
Intervention type: PROCEDURE
Intervention: Prevention Bundles for SSIs
Description: 10 preoperative, intraoperative and postoperative bundles that aim to decrease SSIs rate after their implementation in patients that underwent abdominal surgery.
Study NCT05414175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Specified dose on specified days
Study NCT05125146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBTi
Description: See arm/group description
Study NCT05125146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: See arm/group edescription
Study NCT05905783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for injection
Study NCT05905783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Izokibep
Description: Solution for injection